Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations
As in the previous year, Biophytis did not record any revenues in the first half of 2023.
- As in the previous year, Biophytis did not record any revenues in the first half of 2023.
- The change in net financial expense is mainly due to the valuation of financial liabilities in accordance with IFRS 9.
- As a result of the above, the half-year loss has been significantly reduced, from €12.4 million at 30 June 2022 to €7.8 million at 30 June 2023.
- Continuing pre-clinical development work on Macuneos (BIO201) and its back-up BIO203 and preparing for clinical development in dry AMD.